HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission…
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave…
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave…
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the…
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS),…
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of…
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of…
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer…
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023…
Ms. Gina Chapman Ms. Gina Chapman BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics,…